Alkem Laboratories Limited has informed the Exchange regarding a press release dated September 22, 2025, titled "Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer.".
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alkem Laboratories has launched Pertuza, a 420mg/14mL pertuzumab biosimilar injection, in India for treating HER2-positive breast cancer. The product is indigenously developed and manufactured by Alkem's biotech subsidiary, and a Phase 3 clinical trial confirmed it matches the innovator's product in efficacy, safety, and immunogenicity. The launch aims to improve affordability and access to pertuzumab, which has previously been out of reach for many Indian patients due to high costs. This adds to Alkem's growing oncology biosimilar portfolio, which already includes cetuximab, denosumab, bevacizumab, and romiplostim biosimilars.
This strengthens Alkem's oncology segment and could drive incremental revenue in the high-demand but previously under-served HER2+ breast cancer treatment market in India. Short-term stock impact may be modest, but it supports the company's long-term growth narrative in biosimilars.